SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for AQUABOUNTY TECHNOLOGIES INC (AQB) (CIK 0001603978) (AQB) — Jan 22, 2020

AQUABOUNTY TECHNOLOGIES INC (AQB) (CIK 0001603978)
Date: Jan. 22, 2020 · CIK: 0001603978 · Accession: 0000000000-20-000559

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-235919

Date
January 22, 2020
Author
David A. Frank
Form
UPLOAD
Company
AQUABOUNTY TECHNOLOGIES INC (AQB) (CIK 0001603978)

Letter

January 22, 2020 David A. Frank Chief Financial Officer AquaBounty Technologies, Inc. 2 Mill & Main Place, Suite 395 Maynard, MA 01754 Re:AquaBounty Technologies, Inc. Registration Statement on Form S-1 Filed January 15, 2020 File No. 333-235919 Dear Mr. Frank: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Minahan, Esq.

Show Raw Text
January 22, 2020
David A. Frank
Chief Financial Officer
AquaBounty Technologies, Inc.
2 Mill & Main Place, Suite 395
Maynard, MA 01754
Re:AquaBounty Technologies, Inc.
Registration Statement on Form S-1
Filed January 15, 2020
File No. 333-235919
Dear Mr. Frank:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael J. Minahan, Esq.